Cargando…

Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study

Age is a major contributor to the liver fibrosis rate and its adverse health-related outcomes, including mortality, but older populations are still under-explored. We investigated multimorbidity and inflammatory biomarkers in relation to the increasing liver fibrosis risk to delineate 8-year all-cau...

Descripción completa

Detalles Bibliográficos
Autores principales: Zupo, Roberta, Castellana, Fabio, De Nucci, Sara, De Pergola, Giovanni, Lozupone, Madia, Bortone, Ilaria, Castellana, Marco, Sborgia, Giancarlo, Lampignano, Luisa, Giannelli, Gianluigi, Panza, Francesco, Sardone, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615636/
https://www.ncbi.nlm.nih.gov/pubmed/34829846
http://dx.doi.org/10.3390/biomedicines9111617
_version_ 1784604152157962240
author Zupo, Roberta
Castellana, Fabio
De Nucci, Sara
De Pergola, Giovanni
Lozupone, Madia
Bortone, Ilaria
Castellana, Marco
Sborgia, Giancarlo
Lampignano, Luisa
Giannelli, Gianluigi
Panza, Francesco
Sardone, Rodolfo
author_facet Zupo, Roberta
Castellana, Fabio
De Nucci, Sara
De Pergola, Giovanni
Lozupone, Madia
Bortone, Ilaria
Castellana, Marco
Sborgia, Giancarlo
Lampignano, Luisa
Giannelli, Gianluigi
Panza, Francesco
Sardone, Rodolfo
author_sort Zupo, Roberta
collection PubMed
description Age is a major contributor to the liver fibrosis rate and its adverse health-related outcomes, including mortality, but older populations are still under-explored. We investigated multimorbidity and inflammatory biomarkers in relation to the increasing liver fibrosis risk to delineate 8-year all-cause mortality trajectories in 1929 older adults from the population-based Salus in Apulia Study. Liver fibrosis risk was assumed using the fibrosis-4 (FIB-4) score, assigned to three liver fibrosis risk groups (low, intermediate, high). In the secondary analyses, the APRI score was also calculated to allow for comparisons. Male subjects (prevalence difference: −13.49, 95% confidence interval (CI): −18.96 to −8.03), a higher multimorbidity burden (effect size, ES: −0.14, 95% CI: −0.26 to −0.02), a higher prevalence of physical frailty (ES: 6.77, 95% CI: 0.07 to 13.47), and a more pronounced inflammatory pattern as indicated by tumor growth factor-α circulating levels (ES: −0.12, 95% CI: −0.23 to −0.01) were significantly more common in the highest-risk FIB-4 score group. Liver function characterized by lipid profile and platelet levels worsened with increasing FIB-4 risk score. The 8-year risk of death was nearly double in subjects in the highest-risk FIB-4 score group, even after controlling for possible confounders. Furthermore, a steeper mortality curve was clearly observed for FIB-4 scores as compared with the APRI scoring system with respect to liver fibrosis risk. In conclusion, using a scoring tool based on simple routine biomarkers to detect liver fibrosis risk may enhance biological knowledge of age-related outcomes of chronic liver disease and be helpful in the clinical setting to identify subjects at risk for adverse health-related outcomes, including mortality.
format Online
Article
Text
id pubmed-8615636
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86156362021-11-26 Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study Zupo, Roberta Castellana, Fabio De Nucci, Sara De Pergola, Giovanni Lozupone, Madia Bortone, Ilaria Castellana, Marco Sborgia, Giancarlo Lampignano, Luisa Giannelli, Gianluigi Panza, Francesco Sardone, Rodolfo Biomedicines Article Age is a major contributor to the liver fibrosis rate and its adverse health-related outcomes, including mortality, but older populations are still under-explored. We investigated multimorbidity and inflammatory biomarkers in relation to the increasing liver fibrosis risk to delineate 8-year all-cause mortality trajectories in 1929 older adults from the population-based Salus in Apulia Study. Liver fibrosis risk was assumed using the fibrosis-4 (FIB-4) score, assigned to three liver fibrosis risk groups (low, intermediate, high). In the secondary analyses, the APRI score was also calculated to allow for comparisons. Male subjects (prevalence difference: −13.49, 95% confidence interval (CI): −18.96 to −8.03), a higher multimorbidity burden (effect size, ES: −0.14, 95% CI: −0.26 to −0.02), a higher prevalence of physical frailty (ES: 6.77, 95% CI: 0.07 to 13.47), and a more pronounced inflammatory pattern as indicated by tumor growth factor-α circulating levels (ES: −0.12, 95% CI: −0.23 to −0.01) were significantly more common in the highest-risk FIB-4 score group. Liver function characterized by lipid profile and platelet levels worsened with increasing FIB-4 risk score. The 8-year risk of death was nearly double in subjects in the highest-risk FIB-4 score group, even after controlling for possible confounders. Furthermore, a steeper mortality curve was clearly observed for FIB-4 scores as compared with the APRI scoring system with respect to liver fibrosis risk. In conclusion, using a scoring tool based on simple routine biomarkers to detect liver fibrosis risk may enhance biological knowledge of age-related outcomes of chronic liver disease and be helpful in the clinical setting to identify subjects at risk for adverse health-related outcomes, including mortality. MDPI 2021-11-04 /pmc/articles/PMC8615636/ /pubmed/34829846 http://dx.doi.org/10.3390/biomedicines9111617 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zupo, Roberta
Castellana, Fabio
De Nucci, Sara
De Pergola, Giovanni
Lozupone, Madia
Bortone, Ilaria
Castellana, Marco
Sborgia, Giancarlo
Lampignano, Luisa
Giannelli, Gianluigi
Panza, Francesco
Sardone, Rodolfo
Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study
title Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study
title_full Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study
title_fullStr Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study
title_full_unstemmed Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study
title_short Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study
title_sort liver fibrosis and 8-year all-cause mortality trajectories in the aging cohort of the salus in apulia study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615636/
https://www.ncbi.nlm.nih.gov/pubmed/34829846
http://dx.doi.org/10.3390/biomedicines9111617
work_keys_str_mv AT zuporoberta liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy
AT castellanafabio liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy
AT denuccisara liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy
AT depergolagiovanni liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy
AT lozuponemadia liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy
AT bortoneilaria liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy
AT castellanamarco liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy
AT sborgiagiancarlo liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy
AT lampignanoluisa liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy
AT giannelligianluigi liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy
AT panzafrancesco liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy
AT sardonerodolfo liverfibrosisand8yearallcausemortalitytrajectoriesintheagingcohortofthesalusinapuliastudy